EQRx’s mission to significantly lower the cost of new medicines sparks a lot of questions. Our ongoing series explains our disruptive business model that is #RemakingMedicine.

Mission & Opportunity 1: New Medicines, Radically Lower Prices

Conquering the next frontier of innovation. Founders explain the EQRx business model on track to increase access to new medicines at unprecedented scale

Featuring: Melanie Nallicheri, Alexis Borisy, Dr. Peter B. Bach, Dr. Sandra J. Horning

Mission & Opportunity 2: Dr. Sandra Horning Talks EQRx

One of the industry's most accomplished drug developers explains the need for expanding access to innovation & why that motivated her to help found EQRx.

Featuring: Dr. Sandra Horning

Primed for Commercial Success: The Global Buyers’ Club

EQRx’s unprecedented partnerships with global payers & health systems create a pull-through, rather than push, model for new medicines.

Featuring: Melanie Nallicheri, Kent Rogers, & EQRx advisor David Joyner, former CVS Health and Caremark EVP

Investors’ Perspective: Top-Tier Investors Explain EQRx

Industry-leading investors discuss their unique investment theses and the long-term growth opportunity presented by EQRx’s novel business model.

Featuring: Eli Casdin, Casdin Capital; Keith Meister, Corvex Management LP; Dr. Krishna Yeshwant, GV

Q&A for Investors

From the pipeline to the commercial model, EQRx leadership team responds to questions received after series launch in this recorded webinar.

Featuring: Members of EQRx Leadership Team



Contact us:

Stay in The Loop